Fidelity Parent FMR Reports 9.5% Passive Stake In Natera
FMR and chairman Abigail Johnson reported 13.7 million Natera shares, a position that sits under a certification of no control intent.
FMR, the Boston parent of Fidelity's fund businesses, reported owning 9.5% of Natera's common stock, or 13,659,508.25 shares, in a passive ownership disclosure filed Thursday. Natera, which runs blood-based genetic tests in oncology, women's health and organ health, traded about 9% lower the same day.
Who holds the 13.7 million shares
The holding is measured as of September 30, 2026 and is reported jointly by FMR LLC and Abigail P. Johnson, its chairman and chief executive. FMR has sole voting power over 13,537,105.77 of the shares and no shared voting power. Johnson is listed with the same 9.5% and share count but no voting power of her own.
The percentage uses the SEC's Rule 13d-3 method, which counts shares a holder could acquire within 60 days in both the stake and the share base.
An exhibit names Fidelity Management & Research Company LLC as an entity owning 5% or more of the class. Other listed FMR units include FIAM LLC, Strategic Advisers LLC and Fidelity Management Trust Company. The exhibit says the Johnson family may be deemed a controlling group of FMR.
Passive, by FMR's own certification
FMR certified that the shares were acquired and are held in the ordinary course of business, not to change or influence control of Natera. That is the basis for filing the shorter passive form rather than an activist disclosure.
Natera shares traded at $355.68 in Thursday trading, down about 9% from the prior close of $391.03, for a market value of $56.4 billion. The stake is measured as of September 30, so it predates that move.
A week of Signatera news
Natera sells through its own US sales force and more than 100 laboratory and distribution partners. It processed about 3.5 million tests in 2025 and reported revenue of $2,306.1 million that year, according to its annual report.
The filing arrived in a crowded week for the company. On Tuesday it announced Medicare coverage of Signatera, its test that tracks leftover cancer, in liver cancer. On Wednesday it released three head and neck cancer publications, and on Thursday immunotherapy survival data at a cancer immunotherapy meeting.
The filing says other people have the right to receive dividends or sale proceeds from the shares, but none has an interest above 5% of Natera's common stock.
Sources
- SCHEDULE 13G — FMR LLC re: NATERA INC (NTRA) — SEC EDGAR
- SCHEDULE 13G Exhibit 99 — SEC EDGAR
- Signatera™ Monitoring During First-Line Immunotherapy Showed ctDNA Clearance is Associated with Long-Term Survival Across Four Metastatic Cancers – Company Announcement - FT.com — Financial Times
- Natera Inc. (NASDAQ:NTRA) : Cases :: Law360 — law360.com
- Signatera™ in Head and Neck Cancer: Three New Publications Demonstrate Strong Clinical Performance and Actionability – Company Announcement - FT.com — Financial Times
- Illumina, Inc. v. Natera, Inc. — law360.com
- Medicare Expands Coverage for Signatera™ MRD Test in Hepatocellular Carcinoma — businesswire.com